Buspirone with its unique pharmacological 5-HT1A profile of presynaptic full agonism and postsynaptic partial agonism, when combined with 5-HT1A activation, may potentially be useful in the treatment of depression of socially developmental origin. Here, HTR1A is linked to major depressive disorder.